Although therapies that increase CFTR activity have been successfully developed and approved for the majority of people with CF (18), to date pharmacological ENaC inhibitors as a treatment for CF have failed to translate to clinical use despite a number of efforts to advance this approach (9, 10). This evidence concerns the gene CFTR and cystic fibrosis.